National
Activists differ over calls to cut Uganda aid
Funding of government programs curtailed over anti-gay law
Dickson Mujuni of the RPL AIDS Foundation in Uganda working with youth
peer educators in the East African country. (Photo courtesy of Dickson
Mujuni)
LGBT rights advocates in Uganda and other countries continue to disagree over whether the East African nation should lose foreign aid over a law that imposes a life sentence upon anyone found guilty of repeated same-sex sexual acts.
BuzzFeed late on Sunday reported the Obama administration will divert $6.4 million originally earmarked for the Inter-Religious Council of Uganda – which backs the Anti-Homosexuality Act that Ugandan President Yoweri Museveni signed last month – to other organizations. The website also noted a study designed to identify groups at risk for HIV/AIDS the Centers for Disease Control and Prevention had planned to conduct with a Ugandan university has been suspended.
Jonathan Lalley, a spokesperson for the National Security Council, told BuzzFeed the Obama administration will also redirect roughly $3 million that had been earmarked to promote tourism and biodiversity to non-governmental organizations that work on the issue. The website further reported the Pentagon has suspended or cancelled “near-term invitational travel” for Ugandan officials and plans to relocate events that had been scheduled to take place in the East African country in the coming weeks and months.
Dickson Mujuni of the RPL AIDS Foundation told the Washington Blade on Monday the Inter-Religious Council of Uganda should not receive U.S. aid because he said HIV/AIDS programs the group funds “don’t consider” the “most at-risk populations.”
“Those leaders themselves have been promoting homophobia, putting pressure on the president to assent to the AHB (Anti-Homosexuality Bill) which he did and commending him for signing that bill into law,” he said.
Frank Mugisha, executive director of Sexual Minorities Uganda, a Ugandan LGBT advocacy group, offered a different perspective.
“I don’t support aid cuts in any form,” he told the Blade. “People should know that those are country policies which don’t comply with legislation such as the anti-gay law.”
A number of African advocates who traveled to New York last December to attend the 65th anniversary of the U.N. General Assembly’s ratification of the Universal Declaration of Human Rights told the Blade they oppose efforts to cut foreign aid to Uganda and other countries over their country’s LGBT rights records.
“We’re not asking the U.K. or foreign governments to cut aid to Africa,” said Juliet Mphande, executive director of Rainka Zambia, during a briefing the International Gay and Lesbian Human Rights Commission hosted. “LGBTI individuals are also Africans, so ultimately we all benefit from that aid.”
Ben Summerskill, who recently stepped down as chief executive of Stonewall U.K., last December applauded British Prime Minister David Cameron’s decision to directly channel foreign aid to non-governmental organizations in Uganda and other countries with controversial human rights records. Summerskill spoke to the Blade in New Hampshire hours after the Ugandan Parliament approved the Anti-Homosexuality Bill.
“I don’t think any LGBT campaigner, however strongly they feel about Uganda, would think that it was a good thing that people should starve just so we feel we’re making some progress around human rights for gay people,” said Summerskill.
The Obama administration last month announced after Museveni signed the Anti-Homosexuality Bill into law that it had begun a review of its relationship with Uganda.
A CDC-funded program that fully or partially funded the salaries of 87 employees of the Ugandan Ministry of Health who support the country’s HIV/AIDS response ended on Feb. 28. The World Bank, the Netherlands and other European countries have also cut aid or postponed loans to the East African country after Museveni signed the Anti-Homosexuality Bill.
Uganda receives nearly $300 million each year through the President’s Emergency Plan for AIDS Relief (PEPFAR) to fight the epidemic in the East African country. The Ugandan government in 2013 received more than $485 million in aid from the U.S.
The Washington Post on Sunday reported the White House will send 150 Air Force special operations personnel and several aircraft to Uganda to help the country’s government track down Joseph Kony, leader of the Lord’s Resistance Army whom the International Criminal Court has indicted for war crimes and crimes against humanity that stem from the group’s decades long insurgency against the Ugandan government. The Lord’s Resistance Army is among the issues that U.S. Sen. Jim Inhofe (R-Okla.) and four other members of Congress discussed with Museveni during a meeting on Jan. 23.
The delegation did not meet with Ugandan LGBT rights advocates while in the country, but Inhofe has repeatedly expressed his opposition to the Anti-Homosexuality Bill to the Blade.
“I certainly disagree with the controversial legislation that Uganda may enact in the coming days,” said the Oklahoma Republican before Museveni signed the measure into law. “It is my hope that the country will abandon this unjust and harsh legislation.”
Mugisha is among the Ugandan human rights advocates who signed onto a challenge of the Anti-Homosexuality Bill that the Civil Society Coalition on Human Rights and Constitutional Law filed with the country’s Constitutional Court earlier this month.
“We are cognizant that there are many who share our concerns about Ugandan President Museveni’s recent enactment of the Anti-Homosexuality Act,” said Grant Harris and Stephen Pomper of the National Security Council on Monday. “Ensuring justice and accountability for human rights violators like the LRA [Lord’s Resistance Army] and protecting LGBT rights aren’t mutually exclusive. We can and must do both.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
